Thermo Fisher Scientific CXCL1 Monoclonal Antibody (20326)

Applications

Tested Dilution

Publications

Western Blot (WB)

1 µg/mL

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

1 µg/mL

-

Flow Cytometry (Flow)

0.25 µg per million cells

-

ELISA (ELISA)

0.1-0.4 µg/mL (Detection), 2-8 µg/mL (Capture)

-

Neutralization (Neu)

0.6-9 µg/mL

-

Product Specifications

Species Reactivity

Human, Non-human primate

Published species

Human

Host/Isotype

Mouse / IgG2b

Class

Monoclonal

Type

Antibody

Clone

20326

Immunogen

E. coli-derived recombinant human CXCL1/GRO alpha/KC/CINC-1

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Concentration

0.5 mg/mL

Purification

Protein A/G

Storage buffer

PBS with 5% trehalose

Contains

No Preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2609586

Product Specific Information

In Western blots, this antibody shows approximately 20% cross-reactivity with recombinant human (rh) CXCL2/GRO beta and rhCXCL3/GRO gamma and no cross-reactivity with recombinant rat (rr)CINC-1, rrCINC-2 alpha, rrCINC-2 beta, rrCINC-3, rhMIP-1 alpha, recombinant mouse (rm)MIP-1 alpha, rmMIP-1 beta, rmMIP-1 beta, rhMIP-1 gamma, rmMIP-1 gamma, rmMIP-2, rhMIP-3 alpha, rmMIP-3 alpha, rrMIP-3 alpha, rhMIP-3 beta, or rmMIP-3 beta.

Reconstitute at 0.5 mg/mL in sterile PBS.

Endoxin level is <0.10 EU per 1 µg of the antibody by the LAL method.

Target Information

CXCL1, CXCL2, and CXCL3, also known respectively as GRO alpha, GRO beta (MIP-2 alpha) and GRO gamma (MIP-2 beta), are members of the CXC subfamily of chemokines. Mature CXCL1/2/3 proteins bind with high affinity to the IL-8 receptor type B and are potent neutrophil attractants and activators. In vitro, the processed forms GRO-alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.